inhA promoter mutations: A gateway to extensively drug-resistant tuberculosis in South Africa?

International Journal of Tuberculosis and Lung Disease

Volumn 15, Issue 3, 2011, Pages 344-351

  Müller, Borna ^a   Streicher, E M ^a   Hoek, K G P ^a   Tait, M ^a   Trollip, A ^b   Bosman, M E ^c   Coetzee, G J ^d   Chabula Nxiweni, E M ^e   Hoosain, E ^e   Gey Van Pittius, N C ^a   Victor, T C ^a   Van Helden, P D ^a   Warren, R M ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b Biotec Laboratories SA (Pty) Ltd   (South Africa)

^c NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

^d NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^e Nelson Mandela Bay Municipality   (South Africa)

Author keywords

Drug resistance; katG; MDR TB; MTBDRplus; SNP

Indexed keywords

BACTERIAL PROTEIN; ETHIONAMIDE; INHA PROTEIN; ISONIAZID; KATG PROTEIN; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIAL MUTATION; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; GENE FREQUENCY; GENETIC ASSOCIATION; INDEL MUTATION; MULTIDRUG RESISTANCE; MUTATIONAL ANALYSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROMOTER REGION; SOUTH AFRICA;

ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; GENOTYPE; HUMANS; MOLECULAR PROBE TECHNIQUES; MUTATION; MYCOBACTERIUM TUBERCULOSIS; OXIDOREDUCTASES; PHARMACOGENETICS; PROMOTER REGIONS, GENETIC; SOUTH AFRICA;

EID: 79951637939     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Dye C, Espinal M A, Watt C J, Mbiaga C, Williams B G. Worldwide incidence of multidrug-resistant tuberculosis. J Infect Dis 2002; 185: 1197-1202. (Pubitemid 34297782)
2. Jassal M, Bishai W R. Extensively drug-resistant tuberculosis. Lancet Infect Dis 2009; 9: 19-30.
3. Zhang Y, Yew W W. Mechanisms of drug resistance in Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2009; 13: 1320-1330.
4. Lobue P. Extensively drug-resistant tuberculosis. Curr Opin Infect Dis 2009; 22: 167-173.
5. World Health Organization. Anti-tuberculosis drug resistance in the world. Fourth global report. WHO/TB.97.229. Geneva, Switzerland: WHO, 2008.
6. Hoek K G, Schaaf H S, Gey van Pittius N C, van Helden P D, Warren R M. Resistance to pyrazinamide and ethambutol compromises MDR/XDR-TB treatment. S Afr Med J 2009; 99: 785-787.
7. Department of Health of South Africa. The South African Tuberculosis Control Programme - practical guidelines 2000. 1st ed. Pretoria, South Africa: Department of Health of South Africa, 2000.
8. Department of Health of South Africa. The management of multidrug-resistant tuberculosis in South Africa. 2nd ed. Pretoria, South Africa: Department of Health of South Africa, 1999.
9. Johnson R, Jordaan A M, Pretorius L, et al. Ethambutol resistance testing by mutation detection. Int J Tuberc Lung Dis 2006; 10: 68-73. (Pubitemid 43266280)
10. Louw G E, Warren R M, Donald P R, et al. Frequency and implications of pyrazinamide resistance in managing previously treated tuberculosis patients. Int J Tuberc Lung Dis 2006; 10: 802-807. (Pubitemid 44031396)
11. Johnson R, Warren R, Strauss O J, et al. An outbreak of drug-resistant tuberculosis caused by a Beijing strain in the Western Cape, South Africa. Int J Tuberc Lung Dis 2006; 10: 1412-1414. (Pubitemid 44924598)
12. Victor T C, Streicher E M, Kewley C, et al. Spread of an emerging Mycobacterium tuberculosis drug-resistant strain in the Western Cape of South Africa. Int J Tuberc Lung Dis 2007; 11: 195-201.
13. Gandhi N R, Moll A, Sturm A W, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006; 368: 1575-1580. (Pubitemid 44780738)
14. Johnson R, Warren R M, van der Spuy G D, et al. Drug-resistant tuberculosis epidemic in the Western Cape driven by a virulent Beijing genotype strain. Int J Tuberc Lung Dis 2010; 14: 119-121.
15. Strauss O J, Warren R M, Jordaan A, et al. Spread of a low-fitness drug-resistant Mycobacterium tuberculosis strain in a setting of high human immunodeficiency virus prevalence. J Clin Microbiol 2008; 46: 1514-1516.
16. Barnard M, Allbert H, Coetzee G, O'Brien R, Bosiman M E. Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa. Am J Respir Crit Care Med 2008; 177: 787-792. (Pubitemid 351490566)
17. Johnson R, Streicher E M, Louw G E, Warren R M, van Helden P D, Victor T C. Drug resistance in Mycobacterium tuberculosis. Curr Issues Mol Biol 2006; 8: 97-111.
18. Sandgren A, Strong M, Muthukrishnan P, Weiner B K, Church G M, Murray M B. Tuberculosis drug resistance mutation database. PLoS Med 2009; 6: e2.
19. Banerjee A, Dubnau E, Quemard A, et al. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 1994; 263: 227-230. (Pubitemid 24067929)
20. Guo H, Seet Q, Denkin S, Parsons L, Zhang Y. Molecular characterization of isoniazid-resistant clinical isolates of Mycobacterium tuberculosis from the USA. J Med Microbiol 2006; 55: 1527-1531.
21. Morlock G P, Metchock B, Sikes D, Crawford J T, Cooksey R C. ethA, inhA, and katG loci of ethionamide-resistant clinical Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother 2003; 47: 3799-3805.
22. Herrera L, Jimenez S, Valverde A, Garcia-Aranda M A, Saez-Nieto J A. Molecular analysis of rifampicin-resistant Mycobacterium tuberculosis isolated in Spain (1996-2001). Description of new mutations in the rpoB gene and review of the literature. Int J Antimicrob Agents 2003; 21: 403-408.
23. Victor T C, Jordaan A M, van R A, et al. Detection of mutations in drug resistance genes of Mycobacterium tuberculosis by a dot-blot hybridization strategy. Tubercle Lung Dis 1999; 79: 343-348.
24. Perdigao J, Macedo R, Joao I, Fernandes E, Brum L, Portugal I. Multidrug-resistant tuberculosis in Lisbon, Portugal: a molecular epidemiological perspective. Microb Drug Resist 2008; 14: 133-143.
25. Mlambo C K, Warren R M, Poswa X, Victor T C, Duse A G, Marais E. Genotypic diversity of extensively drug-resistant tuberculosis (XDR-TB) in South Africa. Int J Tuberc Lung Dis 2008; 12: 99-104.
26. Warren R M, Streicher E M, van Pittius N C, et al. The clinical relevance of mycobacterial pharmacogenetics. Tuberculosis (Edinb) 2009; 89: 199-202.